EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics

Davide Carcione iD, Gioconda Brigante, Antonella Carducci, Jari Intra iD, Simone Ambretti iD, Floriana Campanile iD, Gabriele Arcari, Nicasio Mancini, Dario Cattaneo iD, Floriana Gona iD, Mariagrazia Perilli iD, Alessandra Piccirilli und 5 weitere

Pharmaceuticals · 07.02.2026 · 19 (2) · 283

DOI: 10.3390/ph19020283 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 07.02.2026. Verfasst von Davide Carcione und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Microbiology and Virology, ASST Valle Olona, 21013 Gallarate, VA, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, presents a significant public health challenge by limiting effective antimicrobial treatment options. Cefepime, a fourth-generation cephalosporin with broad-spectrum activity, is increasingly compromised by β-lactamase production, efflux pumps, and porin loss. In response, novel cefepime-based β-lactam/β-lactamase inhibitor (BL/BLI) combinations have been developed to overcome these resistance mechanisms. This review examines preclinical and clinical studies on cefepime-based BL/BLI combinations, specifically cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, and cefepime/nacubactam, as found in the PubMed database. Key findings include the restoration of activity against class A ESBLs with cefepime/enmetazobactam, while cefepime/taniborbactam and cefepime/zidebactam show broader inhibition of serine β-lactamases and selected metallo-β-lactamases. Additionally, zidebactam and nacubactam target penicillin-binding protein 2, enhancing bactericidal potency. Preclinical and early-phase clinical trial data indicate potent in vitro activity and favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles. Specifically, the combination of cefepime with enmetazobactam has demonstrated an optimal Cmax/MIC ratio of 8–10, supporting its efficacy in treating MDR Gram-negative infections. Phase III studies are ongoing to confirm efficacy in complicated infections. Cefepime-based BL/BLI combinations are emerging as promising carbapenem-sparing agents, offering broad-spectrum activity, dual mechanisms of action, and encouraging clinical outcomes. These findings support their inclusion in antimicrobial stewardship strategies aimed at mitigating resistance.

Schlagwörter

Stichwörter der Autor:innen

PK/PD featurescefepimeenmetazobactamnacubactamtaniborbactamzidebactamβ-lactam/β-lactamase inhibitor (BL/BLI) combinations

Autor:innen und Institutionen

  • Laboratory of Clinical Microbiology and Virology, ASST Valle Olona, 21013 Gallarate, VA, Italy.
  • Clinical Chemistry Laboratory, Fondazione IRCCS San Gerardo Dei Tintori, 20900 Monza, Italy.
  • Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy.
  • Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy.
  • Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy.
  • Laboratory of Medical Microbiology and Virology, Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy.

ORCID-Profile: Davide Carcione, Jari Intra, Simone Ambretti, Floriana Campanile, Dario Cattaneo, Floriana Gona, Mariagrazia Perilli, Nicholas Geremia, Verena Zerbato, Stefano Di Bella, Giovanna Maria Nicolò, Luigi Principe

Zitieren

APA

Carcione, D., Brigante, G., Carducci, A., Intra, J., Ambretti, S., Campanile, F., Arcari, G., Mancini, N., Cattaneo, D., Gona, F., Perilli, M., Piccirilli, A., Geremia, N., Zerbato, V., Di Bella, S., Nicolò, G. M., & Principe, L. (2026). Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics. Pharmaceuticals, 19(2), 283. https://doi.org/10.3390/ph19020283

Vancouver

Carcione D, Brigante G, Carducci A, Intra J, Ambretti S, Campanile F, et al. Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics. Pharmaceuticals. 2026;19(2):283. doi:10.3390/ph19020283

BibTeX
@article{Carcione2026,
  author = {Carcione, Davide and Brigante, Gioconda and Carducci, Antonella and Intra, Jari and Ambretti, Simone and Campanile, Floriana and Arcari, Gabriele and Mancini, Nicasio and Cattaneo, Dario and Gona, Floriana and Perilli, Mariagrazia and Piccirilli, Alessandra and Geremia, Nicholas and Zerbato, Verena and Di Bella, Stefano and Nicolò, Giovanna Maria and Principe, Luigi},
  title = {Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {2},
  pages = {283},
  doi = {10.3390/ph19020283}
}
Kostenlos starten →